P.D.: Por si interesa a alguien hoy Ahorro y corporacion y recojido en la web de capital Bolsa informa de que las aprobaciones conseguidas ayer por Yondelis son una noticia positiva para Zeltia y su Recomendacion es la de " Comprar " con un Precio Objetivo de 3,90 euros .
************************************************************
Sample drugs considered : Champix, Abilify, Cymbalta, Gardasil , Yondelis , Actemra/Ro-Actemra, Brilinta/Brilique, Ilaris, Prolia, Victoza, Votrient, Daxas, Kuvan, Jevtana, Byetta, Uloric/Adenuric, Gilenya, Cimzia, Banzel/Inovelon, Rapaflo/Silodyx/Urorex, Orencia, and Sprycel.
A consideration of why Canada should answer the European Union's call for heightened IP protection for pharmaceuticals .
This briefing contributes to the current debate around IP rights for pharmaceuticals in Canada.
Against the backdrop of the CETA trade negotiations, Norton Rose Group's Toronto-based head of pharmaceuticals and life sciences, Patrick E. Kierans, and colleagues Kristin Wall and Jill Daley employ a comparative study to highlight why Canada should answer the European Union's call for heightened IP protection for pharmaceuticals.
On average, the EU is approving new drugs faster and enabling patent term restoration, leaving Canadian innovators doubly disadvantaged compared with their second-largest trading partner. Implementing patent term restoration and extending the term of data protection will help to level the playing field with Europe. For the majority of the sampled products, extending data protection by two years appears to provide greater security for innovators without extending overall IP exclusivity for innovative medicines. Increasing the rate of drug approval in Canada will diminish any market exclusivity impact of data protection and patent term restoration, while giving Canadians earlier access to new medicines.
...
PharmaMar Recibe el Ok de la FDA Para Iniciar Fase I con PM54 en Combi con Inmuno Para Posible Tratamiento . PARA EI RELEVO DE LURBINECTEDIN ESTABAN PM184 Y PM14 AMBOS RETIRADOS POR LA CIA. AHORA HAY OTROS DOS FÁRMACOS EN FASE I EN EL INTENTO DE RELEVAR A LURBINECTEDIN : PM54 Y PM534 ... EL PROBLEMA ES QUE AMBOS AÚN ESTAN EN FASE I CON TODO LO QUE ESTO IMPLICA EN CUESTIÓN DE PLAZOS ... YA QUE PARA REALUZAR 3 FASES CLÍNICAS HACEN FALTA DE 12 A 15 AÑOS ... NOS IRÍAMOS AL 2040.